Glyoxalase i in tumor cell proliferation and survival and as a potential target for anticancer therapy

Oncology Research and Treatment

Volumn 37, Issue 10, 2014, Pages 570-574

  Geng, Xiaofang ^a,b   Ma, Ji ^a   Zhang, Fuchun ^a   Xu, Cunshuan ^b  

^a XINJIANG UNIVERSITY   (China)

^b HENAN NORMAL UNIVERSITY   (China)

Author keywords

Anticancer therapy; Cell proliferation and survival; Glyoxalase I; Multidrug resistance; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; GLYOXALASE I INHIBITOR; LACTOYLGLUTATHIONE LYASE; LYASE INHIBITOR; METHYLGLYOXAL; UNCLASSIFIED DRUG; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PHYSICAL CHEMISTRY; REGULATORY MECHANISM; REVIEW; TUMOR CELL; TUMOR DIAGNOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; LACTOYLGLUTATHIONE LYASE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908574739     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000367800     Document Type: Review

References (49)

1. Thornalley PJ: The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990;269:1-11.
2. Sousa Silva M, Gomes RA, Ferreira AE, et al.: The glyoxalase pathway: The first hundred years. and beyond. Biochem J 2013;453:1-15.
3. Thornalley PJ, Rabbani N: Glyoxalase in tumourigenesis and multidrug resistance. Semin Cell Dev Biol 2011;22:318-325.
4. Santarius T, Bignell GR, Greenman CD, et al.: GLO1-A novel amplified gene in human cancer. Genes Chromosomes Cancer 2010;49:711-725.
5. Mannervik B: Molecular enzymology of the glyoxalase system. Drug Metabol Drug Interact 2008; 23:13-27.
6. Xue M, Rabbani N, Thornalley PJ: Glyoxalase in ageing. Semin Cell Dev Biol 2011;22:293-301.
7. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD: Genomic sequence of human glyoxalase-I: Analysis of promoter activity and its regulation. Gene 1999;240:149-155.
8. Rabbani N, Xue M, Thornalley PJ: Activity, regulation, copy number and function in the glyoxalase system. Biochem Soc Trans 2014;42:419-424.
9. Orso F, Corà D, Ubezio B, et al.: Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes. BMC Genomics 2010; 11:355.
10. Xue M, Rabbani N, Momiji H, et al.: Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012;443:213-222.
11. Conboy CM, Spyrou C, Thorne NP, et al.: Cell cycle genes are the evolutionarily conserved targets of the E2F4 transcription factor. PLoS One 2007;2: e1061.
12. Cordell PA, Futers TS, Grant PJ, Pease RJ: The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II. J Biol Chem. 2004;279:28653-28661.
13. Xu Y, Chen X: Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. J Biol Chem. 2006;281:26702-26713.
14. Rabbani N, Shaheen F, Anwar A, et al.: Assay of methylglyoxal-derived protein and nucleotide AGEs. Biochem Soc Trans 2014;42:511-517.
15. Rabbani N, Thornalley PJ: Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino acids 2012;42:1133-1142.
16. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G: Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 2010;11:700-714.
17. Kim KM, Kim YS, Jung DH, et al.: Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. Exp Cell Res 2012;318:152-159.
18. Masterjohn C, Mah E, Park Y, et al.: Acute glutathione depletion induces hepatic methylglyoxal accumulation by impairing its detoxification to dlactate. Exp Biol Med (Maywood) 2013;238:360-369.
19. Brouwers O, Niessen PM, Miyata T, et al.: Glyoxalase- 1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 2014;57:224-235.
20. Hosoda F, Arai Y, Okada N, et al.: Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene 2014 doi:10.1038/onc.2014.57.
21. Cheng WL, Tsai MM, Tsai CY, et al.: Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One 2012;7:e34352.
22. Baunacke M, Horn LC, Trettner S, et al.: Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties. Prostate 2014;74:48-60.
23. Antognelli C, Mezzasoma L, Fettucciari K, et al.: Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells. Prostate 2013;73:121-132.
24. Wang Y, Kuramitsu Y, Tokuda K, et al.: Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma. Electrophoresis 2014;35:2195-2202.
25. Wang Y, Kuramitsu Y, Ueno T, et al.: Glyoxalase I (GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues. Anticancer Res 2012;32:3219-3222.
26. Dong L, Zhou Q, Zhang Z, et al.: Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res 2012;38:1077-1085.
27. Zhang Z, Dong L, Sui L, et al.: Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011;21:213-221.
28. Hu X, Yang X, He Q, et al.: Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation. Biotechnol Lett 2014; 36:257-263.
29. Hayes JD, McMahon M: NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009;34: 176-188.
30. Wang XJ, Sun Z, Villeneuve NF, et al.: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-1243.
31. Loarca L, Sassi-Gaha S, Artlett CM: Two -dicarbonyls downregulate migration, invasion, and adhesion of liver cancer cells in a p53-dependent manner. Dig Liver Dis 2013;45:938-946.
32. Antognelli C, Mezzasoma L, Fettucciari K, Talesa VN: A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. Int J Biochem Cell Biol 2013;45:836-844.
33. Sakamoto H, Mashima T, Kizaki A, et al.: Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000;95:3214-3218.
34. Nass N, Brömme HJ, Hartig R, et al.: Differential response to -axoaldehydes in tamoxifen resistant MCF-7 breast cancer cells. PLoS One 2014;1: e101473.
35. Tsuruo T, Naito M, Tomida A, et al.: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
36. Birkenmeier G, Stegemann C, Hoffmann R, et al.: Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PloS One 2010;5:e10399.
37. Speer O, Morkunaite-Haimi S, Liobikas J, et al.: Rapid suppression of mitochondrial permeability transition by methylglyoxal. J Biol Chem 2003;278: 34757-34763.
38. Godbout JP, Pesavento J, Hartman ME, et al.: Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase C delta. J Biol Chem 2002;277:2554-2561.
39. Chan WH, Wu HJ, Shiao NH: Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 2007;100:1056-1069.
40. Zhang S, Liang X, Zheng X, et al.: Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int J Clin Exp Pathol 2014;15:2079-2090.
41. Taniguchi H, Horinaka M, Yoshida T, et al.: Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther 2012;11:2294-2300.
42. Thornalley PJ, Edwards LG, Kang Y, et al.: Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo: Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 1996;51:1365-1372.
43. More SS, Vince R: Inhibition of glyoxalase I: The first low-nanomolar tight-binding inhibitors. J Med Chem 2009;52:4650-4656.
44. Liu M, Yuan M, Luo M, et al.: Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis. Biophys Chem 2010;147:28-34.
45. Bartyik K, Turi S, Orosz F, Karg E: Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukaemia. Eur J Cancer 2004;40:2287-2292.
46. Santel T, Pflug G, Hemdan NY, et al.: Curcumin inhibits glyoxalase 1 - a possible link to its anti-inflammatory and anti-tumor activity. PLoS One 2008;3:e3508.
47. Yuan M, Luo M, Song Y, et al.: Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg Med Chem 2011;19:1189-1196.
48. Takasawa R, Saeki K, Tao A, et al.: Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem 2010;18: 7029-7033.
49. Helgager J, Li J, Lubensky IA, et al.: Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents. J Oncol 2010;2010:373491.